Jun 30, 2022 7:00 am EDT Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
Jun 7, 2022 7:00 am EDT Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
May 12, 2022 9:05 am EDT Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
May 5, 2022 7:00 am EDT Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
Apr 28, 2022 7:00 am EDT Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
Mar 3, 2022 8:30 am EST Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Feb 16, 2022 8:30 am EST Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study